Dr. Robert Docherty did his degree and PhD. at Strathclyde University and joined ICI/Zeneca in 1988 where he worked on the solid-state structure and crystallization of dyes, pigments, biocides,...
By Dr. Bob Docherty, Pfizer The focus would be on solid form screen & selection, crystallization process development, pre-formulation evaluations, particle engineering and projecting the API attributes to drug...
By Dr. Ahmad Sheikh, AbbVie While new chemical entities represent majority of the drugs approved in the last five years, the diversity and complexity of these molecules continue...
By Dr. Jeremy M. Merritt, Eli Lilly and Co. Abstract: pending
